Fertility

 ALIFE2
 
 ANTARCTICA 2
 
 exIUI
 
 FOAM
 
 IVF 38+
 Medium II
 
 SCRaTCH OFO
 
 SelecTIMO
 STIM
 
 T4-LIFE
 TRUST
 
 ZinenZwanger
 
 SCRaTCH
 ALIFE
 Bedrust
 ESEP
 H2Olie
 Freeze-all (progesterone)
 IMPROvEMENT
 INeS
 inSIGHT
 Lifestyle
 MASTER
 M-ovin"
 OPTIMIST
 > Promise
 PRORAILS
 SUPER

 AID-study
 Antarctica study
 Congeno study
 DESH trial
 ENDO-RECEPT
 Follikel diameter
 IVM study
 L-Age
 Medium
 Metex
 Pr_OVIN
 PRIMA
 SETI
 THL
 

 

Promise trial

 

PROgesterone in recurrent MIScarriagE

 

Go to the Promise website

 

Objective

To assess improvement in live birth rate after progesterone supplementation.

In the absence of properly randomized controlled trials that assessed the efficacy of progesterone in women with RM, a clinical trial with adequate randomization is necessary. In clinical practice, women with RM are frequently seeking advice about the indication for progesterone treatment. Therefore, we have designed a randomized clinical trial to assess the efficacy of progesterone, as compared with placebo, on the live birth rate in women with at least 3 preceding miscarriages.

 

Study design

Randomized, double-blind, placebo controlled multicentre study

 

Study population

Women with recurrent miscarriage, i.e. at least 3 miscarriages, aged 18-39 years, conceiving spontaneously

 

Intervention

One group receives vaginal progesterone pessaries 2x 200 mg twice daily (Utrogestan®) and the other group receives placebo pessaries of identical appearance twice daily.

 

Outcome measures

Primary: Live birth rate.

Secondary: Miscarriage rate, gestational age at delivery, adverse events, serum progesterone luteal phase.

 

Project leaders

Dr Arri Coomarasamy, MBChB, MD, MRCOG
Senior lecturer and Consultant
Gynaecologist
Birmingham Women’s Hospital
Metchley park Road
B15 2TG Birmingham, UK
arricoomar@blueyonder.co.uk

 

Dr. M. Goddijn

AMC (H4-205)

Meibergdreef 9

1105 AZ Amsterdam ZO

M.Goddijn@amc.uva.nl